

CURRICULUM VITAE

Personal Details

Date of Birth and Gender	15/07/1953, Female
First and Last Names	Christine CHOMIENNE
Country	France

Current Position

VivaAdju SAS, Co-Founder and Vice-Chair of the Scientific Advisory Board,
Emeritus Professor of Cellular Biology and Hematology,
chomienne.christine@gmail.com

Organization/Company

Code RNSR	Organization	Laboratory	Code unite	Code postal	City/Town
201420724V	VIVADJU Université Paris Cité	Normal and Pathological Hematopoiesis	UMRS-1342 Group 6	75010 75010	Paris Paris

Other Activities

2019 - Vice Chair Horizon Europe Cancer Mission Board
 2023 -. Member Scientific and Ethics Advisory Board CSA Can.Heal
 2023 -. Member Scientific and Ethics Advisory Board CSA Can.Serv
 2024 - Member of the Strategic Committee of Fondation pour la Recherche sur le Cancer ARC (Association of Research in Cancerology)
 2015 - Past President of the European Hematology Association (EHA)

Professional Experience

Research direction and programs

2020 - 2026 Member executive board Inserm
 2019 - Present Vice-Chair Horizon Europe Cancer Mission Board I
 2016 - 2019 Head of the Research and Innovation Department – INCA (Institut National du Cancer)
 2016 - 2019 Head of the ITMO Cancer (Institut Multi Organisms and IT Cancer (Institut Thématique) AVIESAN (Alliance of Life Sciences) and INSERM (Institut National de la Santé et de la Recherche Médicale)
 1992 – 2019 Director Research Laboratory (INSERM-University UMRS 1131)

Hospital functions

1984 - 2019 Consultant in Hematology, Hospital Saint Louis
 2005 - 2019 Head of the Cellular Biology Department, Hospital Saint Louis

Teaching Functions

1999 - 2021 Professor of Cell Biology, University of Paris Diderot (UPD), Paris 7, Exceptional Class
 1996 - 2021 Coordinator of Research Masters “Molecular Biology and Function of Hematopoietic cells”
 1997 - 2021 Coordinator (with C. Dosquet) of DU of Cellular Therapy, University of Paris Diderot (UPD)

Previous Activities

European & International Functions

1990 - 1995 Coordinator FP3-Biomed I BMH11144: “Molecular targeting of leukemia differentiation therapy”
 1993 - 1996 Coordinator International Scientific Workshops “RT-PCR in AML3”
 1998 - 2001 Coordinator Euroworkshops on “Animal Models as tools for Hematology Research”
 2004 - 2007 Member of the Scientific Council of Leukemia Research Fund (LRF) - current Bloodwise (UK)
 2007 - 2011 Chair of the Communication and Press Committee of the EHA
 2009 - 2011 Member of the International Committee of the American Hematology Association (ASH)
 2010 - 2014 Coordinator of the Scientific Workgroup Leukemic Stem Cells (EHA)
 2010 - 2015 Coordinator of the 7th PCRD ITN European Network on Cancer Stem Cell Training (EuroCSCT)
 2010 - 2016 Secretary of the European School of Hematology (ESH)
 2011 - 2013 President Elect of the EHA
 2011 - 2013 Committee member of the Training in Translational Research in Hematology Program (ASH-EHA)
 2011 - 2014 Coordinator of the Dual Master Program Molecular Medicine Sharjah Emirate University- UPD
 2011 - 2015 Chair of the National Societies Committee of the EHA
 2011 - 2015 Member of the European Affairs Committee (EHA)
 2011 - 2015 President of the EHA

2012 - 2015 Board member of Trials Acceleration Program, Blood Wise (UK)
 2013 - 2015 Member of the Education Program of the European Alliance of Personalized Medicine
 2018 - 2019 Member WP5 IMI2 "Harmony"

Academia-research organization functions

1992 - 2019 Director Research Laboratory (University-CNRS then INSERM-University current UMRS 1342 Group 6)
 1995 - 1999 Member of the Scientific Council of INSERM
 2000 - 2010 Member of the Commission Structures Effectifs, Hospital Saint Louis
 2004 - 2007 Member of the Scientific Council of the LRF - current Bloodwise (UK)
 2004 - 2008 Member of Scientific Committee, Cancer & Immunology CSS2, INSERM
 2005 - 2009 Co-Director of Center of Clinical Investigation and Biotherapy (CIC-BT), Paris
 2005 - 2019 Head of the Cell Biology Department-Hospital Saint Louis, Paris
 2006 - 2009 Board member (UPD)
 2006 - 2010 Member of the Education Committee (EHA)
 2006 - 2011 Member of Scientific committee of the Institut Universitaire d'Hématologie (IUH)
 2006 - 2011 Board member of the Region Ile de France, Domain of Major interest "StemPôle"
 2007 - 2013 Co-Coordinator with Daniel Louvard of the Paris Cancer Stem Cell Network (Inca-Cancéropôle)
 2010 - 2014 Board member of the Region Ile de France Domain of Major interest DIM Cancéropôle
 2010 - 2015 Scientific committee member (CN5) of the ARC
 2013 - 2018 Board member of the UPD

Academia teaching function

1984 - 1990 Instructor in Biophysics, UPD Medical School
 1990 - 1995 Associate Professor of Cellular Biology, UPD
 1995 - Present Professor of Cellular Biology, UPD, Exceptional Class (1995-)
 1996 - 2000 Director of the PhD School « Blood & Vessels », UPD
 1996 - 2019 Coordinator of Master Research Programme "Function and Molecular Biology of Hematopoietic Cells"
 1997 - 2019 Coordinator of French National Biotherapy Course, UPD
 2005 - 2014 Coordinator of the "Blood Cell Biology Section" of the PhD School B2T, UPD
 2006 - 2010 Member of the Education Committee (EHA)
 2008 - 2011 Director of the PhD Schools (23) of UPD
 2010 - 2014 Coordinator of the Master Research Program "Biotherapies & Drugs", UPD

Public-Private Partnerships

2010 - 2012 Member of the Scientific Committee of Alliance pour la Recherche & Innovation des Industries de Santé

Prizes and Awards

1990 Prix Gustave Roussy
 1992 Prix de l'Académie des Sciences
 1995 Prix Deneboudé (La Ligue, Comité Pyrénées Atlantique)
 2007 Chevalier de la Légion d'Honneur
 2009 Prix Académie des Sciences
 2017 Officier de la Légion d'Honneur
 2021 Jean Bernard Lifetime Achievement Award, EHA

Academic Career Interruption

NA

Education

1983 MD (University of Paris 6)
 1989 PhD Doctorate in Human Biology (University of Paris 7)

Publications

More than 260 publications , h-index 77

5 Major Publications

Quel est l'apport majeur de cette publication ?

1	CHOMIENNE C, BALLERINI P, BALITRAND N, AMAR M, BERNARD JF, BOIVIN P, DANIEL MT, BERGER R, CASTAIGNE S, DEGOS L. Retinoic Acid Therapy for Promyelocytic Leukemias <i>Lancet</i> 2 , 746-747,1989. PMID: 2570995	First clinical result in France of complete remission of acute promyelocytic leukemias using retinoic acid. In vitro and in vivo demonstration of the effectiveness of the all-trans metabolite alone compared to 13-cis
2	De THE H, CHOMIENNE C , LANOTTE M, DEGOS L, DEJEAN A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus . <i>Nature</i> 347 :558-561, 1990. PMID: 2170850	Demonstration for the first time that the chromosomal translocation characteristic of promyelocyte leukemia produces a fusion oncogene involving the retinoic acid receptor gene RAR
3	CHARRAD R-S, LI Y, DELPECH B, BALITRAND N, CLAY D, JASMIN C, CHOMIENNE C , SMADJA-JOFFE F Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. <i>Nature Medicine</i> 5 (6) : 669-76, 1999. PMID: 10371506	First demonstration that a second physiological agent, hyaluronic acid, ligand for the membrane protein CD44, induces the in vitro differentiation of acute myeloid leukemias (including acute promyelocytic leukemias)
4	PADUA RA, LARGHERO J, ROBIN M, LE POGAM C, SCHLAGETER M, MUSZLAK S, FRIC J, WEST R, ROUSSELOT P, PHAN TH, MUDDE L, TEISSERENC H, CARPENTIER AF, KOGAN S, DEGOS L, PLA M, BISHOP M, STEVENSON F, CHARRON D, CHOMIENNE C Fusion-oncogene DNA-based vaccine induces protective immunity: targeted therapy in a murine APL model <i>Nature Medicine</i> 9 (11) 1413-7, 2003. PMID: 26378812	First demonstration that a plasmid DNA comprising a DNA sequence of the fusion gene of promyelocyte leukemia associated with retinoic acid induced immune remission in mice and induced complete remission. Highlighting the role of retinoic acid as an adjuvant
5	CAYE A, STRULLU M, GUIDEZ F, CASSINAT B, GAZAL S, FENNETEAU O, LAINEY E, NOURI K, NAKHAEI-RAD S, DVORSKY R, LACHENAUD J, PEREIRA S, VIVENT J, VERGER E, VIDAUD D, GALAMBRUN C, PICARD C, PETIT A, CONTET A, POIREE M, SIRVENT N,MECHINAUD F, ADJAOUD D, PAILLARD C, NELKEN B, REGUERRE Y, BERTRAND Y, HÄUSSINGER D, DALLE JH, AHMADIAN MR, BARUCHEL A, CHOMIENNE C , CAVE H. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. <i>Nature Genetics</i> 47 (11):1334-40, 2015. PMID: 26457648	Highlighting genomic alterations of the RAS pathway and the PRC2 epigenetic pathway in chronic myelomonocytic disease in infants

Valorization

1. Patent: April 2002 (EP 02 291 069.9) relating to "Combined vaccine with DNA and biological modifiers for treatment of cancer", the inventors are Christine Chomienne, Rose Ann Padua and Dominique Charron. Extension PCT filed April 2003 (PCT/IB03/01600), EU (BET 04P0891 European Patent Application No. 03717465.3, issued in 2013, EP 1 496 937 B1) and Japan (issued in 2011, no. JP 4,354,826). Assigned to United States no. 02291069.9, granted in 2008 on PML-RARaFrC and ATRA in APL, no. US 7,381,710 and granted in 2013 on DNA immunogenic defined in any cancer, Prosecutor's File No. PO8427USO1/B, Confirmation Number: 6468 US No. 8673 870.
2. Patent filed in 2009 in Europe (BET 08P1378) "Kanamycin antisense nucleic acid for the treatment of cancer ". Inventors: Christine Chomienne & Rose Ann Padua. PCT filed in March 2010 (PCTEP2010/054039, EP 09290 224.6) BET 11P2576 - US 13/258173. Granted in Europe and the United States in 2015 and in Canada in 2019.
3. VivAdju/INSERM patent filed in Europe in March 2023 (EP23305447.7). "pVAX14 nucleic acid formulated with a nano-vehicle in combination with four-trans retinoic acid (ATRA) to activate immune responses". Inventors: Rose Ann Padua, Bruno Pitard, Christine Chomienne, Patricia Krief and Marika Pla.
4. VivAdju/INSERM patent filed in Europe in March 2023 (EP23305449.3). "Combination of pVAX14 and four-trans retinoic acid (ATRA) with immune checkpoint inhibitor for the treatment of cancer". Inventors: Rose Ann Padua, Bruno Pitard, Christine Chomienne, Patricia Krief and Marika Pla.

Private activity

Co-Founder and member of the SAB, VivAdju SAS Jan 2023, Incubated by Paris Biotech Santé since Nov 2022.
Co-Founder of Vivavacs SAS 2007-2013, Incubated by Paris Biotech Santé (2006-2009), Closed voluntarily in 2013.
Winner of the OSEO 2008 "creation-development" competition. Project leader: Christine Chomienne.

